News & Press
ACGP Submits Comments to CMS on CRUSH Initiative
For millions of Americans living with advanced cancer, access to comprehensive genomic profiling is not an abstract policy question. It is the critical first step toward identifying whether a targeted therapy may extend or save their life. ACGP shares CMS’s commitment to eliminating fraud, waste, and abuse, and we firmly believe this goal can be achieved without undermining the remarkable progress that precision oncology has made possible. Read the full letter below.
The Access to Comprehensive Genomic Profiling Coalition Announces the Appointment of Dr. John Fox as Chair
We are pleased to announce the appointment of John Fox, MD, MHA, as Chair of ACGP. Dr. Fox is currently the Senior Medical Director of the Americas, Market Access, for Illumina, where he is accountable for working with payers and employers to expand access to genomic testing for cancer, rare and infectious diseases, and cardiac and prenatal applications.
“Genomics continues to transform the practice of oncology which translates into improved outcomes and better value—but only if providers can access and accurately apply the technology. I look forward to working with fellow members of ACGP to make the promise of comprehensive genomic profiling a tangible benefit to the patients we serve.” – Dr. John Fox
The Access to Comprehensive Genomic Profiling Coalition Welcomes Merck as a Member
WASHINGTON, Dec. 16, 2022 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Merck to its coalition of companies advocating for coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S. health insurers.
The Access to Comprehensive Genomic Profiling Coalition Welcomes Blueprint Medicines as a Member
WASHINGTON, April 15, 2022 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Blueprint Medicines to its coalition of companies advocating for coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S. health insurers.
The Access to Comprehensive Genomic Profiling Coalition Welcomes Strata Oncology as a Member
WASHINGTON, July 12, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Strata Oncology, a precision oncology company advancing molecular indications for cancer therapies. ACGP is comprised of diagnostics companies, laboratory service providers, and CGP industry stakeholders to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.
The Access to Comprehensive Genomic Profiling Coalition Welcomes Two New Members – PGDx and Sema4
WASHINGTON, June 23, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Personal Genome Diagnostics (PGDx), a leader in cancer genomics, and Sema4, a patient-centered health intelligence company, to its coalition of diagnostics companies, laboratory service providers, and CGP industry stakeholders to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.